Novartis: Sandoz recalls stomach drug in the US

(CercleFinance.com) - Sandoz, the generics unit of Swiss drugmaker Novartis, said that it has issued a voluntary recall of its Ranitidine stomach drug in the US, because of contamination with a substance that could cause cancer.


Sandoz is voluntarily recalling all quantities and batches, due to NDMA exceeding levels established by the FDA, it said.

NDMA is a known environmental contaminant found in water and foods, including meat, dairy products, and vegetables. It is classified as a probable human carcinogen.

Ranitidine is indicated for the treatment of benign gastric ulcer, reflux esophagitis and post-operative peptic ulcer.

To date, Sandoz has not received any reports of adverse events relating to use of the product, it said.

Copyright (c) 2019 CercleFinance.com. All rights reserved.